Synagis and Hepatic function abnormal - a phase IV clinical study of FDA data

Summary:

Hepatic function abnormal is reported as a side effect among people who take Synagis (palivizumab), especially for people who are male, 0-1 old, have been taking the drug for < 1 month also take Ilaris, and have Chronic infantile neurological cutaneous and articular syndrome.

The phase IV clinical study analyzes which people have Hepatic function abnormal when taking Synagis. It is created by eHealthMe based on reports of 19,108 people who have side effects when taking Synagis from the FDA, and is updated regularly.

What is Synagis?

Synagis has active ingredients of palivizumab. eHealthMe is studying from 19,114 Synagis users. Check the latest studies of Synagis.

What is Hepatic function abnormal?

Hepatic function abnormal is found to be associated with 1,446 drugs and 2,016 conditions by eHealthMe. Check the latest studies of Hepatic function abnormal.

On Apr, 23, 2026

19,108 people reported to have side effects when taking Synagis.
Among them, 26 people (0.14%) have Hepatic function abnormal.

Could Synagis cause Hepatic function abnormal?

Among these 26 people:

How long have people been on Synagis when they have Hepatic function abnormal? *

What is the gender of people who have Hepatic function abnormal when taking Synagis? *

female: 13.04 %
male: 86.96 %

What is the age of people who have Hepatic function abnormal when taking Synagis? *

What are other drugs people take besides Synagis? *

What are other side effects people have besides Hepatic function abnormal? *

Aspartate Aminotransferase Increased: 9 people, 34.62%
Alanine Aminotransferase Increased: 9 people, 34.62%
Rashes (redness): 7 people, 26.92%
Fever: 6 people, 23.08%
Adenovirus Infection: 4 people, 15.38%
Oral Mucosal Eruption (a sudden appearing of rash on mucous membrane of mouth): 4 people, 15.38%
Diarrhea: 4 people, 15.38%
Asthma: 4 people, 15.38%
Rhinorrhea (watery mucus discharge from the nose): 4 people, 15.38%
Hand-Foot-And-Mouth Disease: 4 people, 15.38%

What are the existing conditions these people have? *

Chronic Infantile Neurological Cutaneous And Articular Syndrome (a rare genetic periodic fever with joints inflammation): 7 people, 26.92%
Upper Respiratory Tract Inflammation: 4 people, 15.38%
Respiratory Syncytial Virus Bronchiolitis (a lower respiratory tract infection due to virus): 4 people, 15.38%
Impetigo (contagious skin infection): 4 people, 15.38%
Fever: 4 people, 15.38%
Anaemia Neonatal: 4 people, 15.38%
Respiratory Syncytial Virus Infection (viral disease of respiratory system): 3 people, 11.54%
Premature Baby: 3 people, 11.54%
Chronic Respiratory Disease: 2 people, 7.69%
Bronchopulmonary Dysplasia (chronic lung disorder in infants - enlargement of an organ or tissue by the proliferation of cells of an abnormal type): 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Synagis and have Hepatic function abnormal?

- Check whether Hepatic function abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Synagis:

Synagis (19,114 reports)

Browse all side effects of Synagis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic function abnormal:

Hepatic function abnormal (1,446 drugs)

Browse all the conditions that are associated with Hepatic function abnormal:

Hepatic function abnormal (2,016 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on palivizumab (the active ingredients of Synagis) and Synagis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.